AMT-130 Emerging Drug Insight and Market Forecast - 2032

“AMT-130 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about AMT-130 for Huntington's disease in the 7MM. A detailed picture of the AMT-130 for Huntington's disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the AMT-130 for Huntington's disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AMT-130 market forecast, analysis for Huntington's disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Huntington's disease.

Drug Summary

AMT-130 is a gene therapy for Huntington's disease; rare, fatal, neurodegenerative genetic disorder that affects motor function and leads to behavioral symptoms, and cognitive decline in young adults, resulting in total physical and mental deterioration. AMT-130 consists of an AAV5 - vector carrying an artificial microRNA specifically tailored to silence the huntingtin gene, leveraging the proprietary miQURE silencing technology. The therapeutic goal is to inhibit the production of the mutant protein (mHTT). Using AAV vectors to deliver microRNAs (miRNAs) directly to the brain for non-selective knockdown of the huntingtin gene represents a highly innovative and promising approach to treating Huntington's disease.

AMT-130, a gene therapy candidate for Huntington's disease, is differentiated in that:

• AMT-130 targets deep brain structures associated with disease onset pathology.
• AMT-130 silences mutant huntingtin protein at levels that have not been achieved with other agents.
• AMT-130 targets the accumulation of the exon 1 HTT fragment, the most toxic source of abnormal protein aggregation in Huntington's disease.

The drug has received orphan drug designation and fast track designation from the US FDA for the treatment of Huntington's disease and is currently in Phase I/II clinical development (NCT05243017, NCT04120493).The studies were designed to investigate the safety, tolerability, and efficacy signals of multiple ascending doses of striatally administered AMT-130 total Huntingtin gene (HTT) lowering therapy in patients with early manifest Huntington's disease; a randomized, double-blind, sham control study was carried out to investigate the safety, tolerability, and efficacy signals of multiple ascending doses of striatally administered AMT-130 total Huntingtin gene (Both studies are recruiting trial subjects, and their primary completion dates are March 2027 and April 2029, respectively.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the AMT-130 description, mechanism of action, dosage and administration, research and development activities in Huntington's disease.
• Elaborated details on AMT-130 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AMT-130 research and development activity in Huntington's disease in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AMT-130 (Deutetrabenazine).
• The report contains forecasted sales of AMT-130 for Huntington's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Huntington's disease.
• The report also features the SWOT analysis with analyst views for AMT-130 in Huntington's disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AMT-130 Analytical Perspective

In-depth AMT-130 Market Assessment

This report provides a detailed market assessment of AMT-130 in Huntington's disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

AMT-130 Clinical Assessment

The report provides the clinical trials information of AMT-130 in Huntington's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Huntington's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AMT-130 dominance.
• Other emerging products for Huntington's disease are expected to give tough market competition to AMT-130 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AMT-130 in Huntington's disease.
• This in-depth analysis of the forecasted sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AMT-130 in Huntington's disease.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of AMT-130?
• What is the clinical trial status of the study related to AMT-130 in Huntington's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AMT-130 development?
• What are the key designations that have been granted to AMT-130 for Huntington's disease?
• What is the forecasted market scenario of AMT-130 for Huntington's disease?
• What are the forecasted sales of AMT-130 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Huntington's disease and how are they giving competition to AMT-130 for Huntington's disease?
• Which are the late-stage emerging therapies under development for the treatment of Huntington's disease?

This product will be delivered within 2 business days.